RxDoctor Payments Data

Triet Nguyen, MD

Ophthalmology · Westminster, CANPI 1306807789

Payments from drug & device makers

$103,216in general payments, 2019–2025

Across 1,981 payments — averaging $52.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$52K
  • AbbVie$6K
  • Bausch & Lomb Americas Inc.$5K
  • Alcon$4K
  • Mallinckrodt Hospital Products Inc.$4K
  • Aerie Pharmaceuticals, Inc.$4K
  • plus $28K from 30 others

What the payments were for

  • Consulting fees$2,7503%
  • Speaking & faculty fees$40,85540%
  • Travel & lodging$1,8172%
  • Food & beverage$57,77456%
  • Gifts$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$103,216 in reported general payments places this provider in the 90th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$1,421,710
Medicare patients
640
Services billed
9,202

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ActharCorticotropin69$5,800,983
MieboPerfluorohexyloctane/Pf2,576$2,004,079
XiidraLifitegrast1,976$1,842,462
CequaCyclosporine2,122$1,602,156
TyrvayaVarenicline Tartrate869$627,847
ProlensaBromfenac Sodium1,372$485,501
ZerviateCetirizine Hcl657$376,823
RestasisCyclosporine448$376,525
RocklatanNetarsudil Mesylat/Latanoprost642$257,116
LumiganBimatoprost627$229,688
BromsiteBromfenac Sodium721$195,608
VevyeCyclosporine246$187,318
Cyclosporine345$175,659
RhopressaNetarsudil Mesylate369$167,668
XdemvyLotilaner71$129,963

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Mallinckrodt Hospital Products Inc.Acthar$4,187$5,800,98369 claims
Bausch & Lomb Americas Inc.Miebo, Xiidra, Vyzulta$4,682$3,940,1604,836 claims
Sun Pharmaceutical Industries Inc.Cequa, Bromsite$51,674$1,797,7642,843 claims
AbbVieRestasis, Lumigan, Combigan, Alphagan P$6,464$775,0811,639 claims
Oyster Point Pharma, Inc.Tyrvaya$3,477$627,847869 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Bepreve, Lotemax Sm, Besivance, Zylet$2,709$589,4371,763 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$3,735$424,7841,011 claims
Eyevance Pharmaceuticals LLCZerviate, Tobradex St$3,678$389,317712 claims
Harrow Eye, LLCVevye$1,231$187,318246 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$1,931$129,96371 claims
Akorn, Inc.Azasite, Zioptan, Betimol$706$123,552438 claims
NovartisIlevro$1,940$112,945302 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Westminster

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →